ADMA Biologics Inc vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $24.61. Which is the better fit depends on your goals.
| ADMA | CWEB | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $60.13 |
52-Week Low | $7.60 | $17.70 |
Enterprise Value | $2.25B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.
The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →